AVANT targets its efforts where it can add the greatest value to the development of its products and technologies. Our goal is to demonstrate clinical proof-of-concept for each product, and when appropriate seek excellent partners to help see those products through to commercialization. This approach allows us to maximize the overall value of our technology and product portfolios while best ensuring the expeditious development of each individual product.

We have actively developed and acquired innovative technologies - especially novel approaches to vaccine creation. Today our broad intellectual property position allows us to respond quickly and leverage our expertise into many different areas as opportunities and needs arise.

AVANT is currently seeking the following types of business opportunities:

	Worldwide development and marketing partner(s) for AVANT's TP10 and TP20 complement inhibitor programs
	Worldwide development and marketing partner(s) for AVANT's CETi cholesterol management vaccine
	Phase 2/3 vaccine acquisition candidates

For more information please contact:

Ron Newbold
Senior Vice President, Business Development
Phone: (908) 454-7120 x312
Email: rnewbold@celldextherapeutics.com